File
More Virtual Posters
Search for Terms or Answers
×
![]()
Search for Terms or Answers
Andrea Rubbert-Roth, Kevin Winthrop, Andra Balanescu, Adam Mayer, Shu Huang, Doug Ashley, Lani Wegrzyn, Thomas Iyile, Ralph Lippe, Emily Scherer, Jeffrey R. Curtis
Abstract or description:This analysis of U.S. electronic health records and linked insurance claims data (2019–2024) included 132,682 patients with psoriatic arthritis (PsA), of whom 1,163 developed new-onset inflammatory bowel disease (IBD). Ten predictors of IBD were identified at PsA diagnosis, with 28.1% of all patients displaying ≥1 predictor. The highest-risk predictors were blood in stool, family history of IBD, and gastroenteritis/gastritis. Additionally, 14 early indicators for new-onset IBD were identified, with 86.2% of patients exhibiting ≥1 indicator within 180 days prior to IBD diagnosis. These findings suggest a need for heightened clinical suspicion for IBD in at-risk patients with PsA to support earlier recognition and diagnosis of IBD, and more informed treatment decisions.
Results from the cohorts in this real-world study were captured during routine clinical practice and are descriptive in nature only. Statistical significance has not been established.
The Medical Affairs + Health Impact department of AbbVie Inc. is the copyright owner of this presentation and has paid RheumNow to host this content. AbbVie is solely responsible for all written content within this presentation.
© 2026 AbbVie Inc. All rights reserved. ABBV-US-02460-MC. v1.0 Approved June 2026
Andrea Rubbert-Roth, Kevin Winthrop, Andra Balanescu, Adam Mayer, Shu Huang, Doug Ashley, Lani Wegrzyn, Thomas Iyile, Ralph Lippe, Emily Scherer, Jeffrey R. Curtis
Abstract or description:This analysis of U.S. electronic health records and linked insurance claims data (2019–2024) included 132,682 patients with psoriatic arthritis (PsA), of whom 1,163 developed new-onset inflammatory bowel disease (IBD). Ten predictors of IBD were identified at PsA diagnosis, with 28.1% of all patients displaying ≥1 predictor. The highest-risk predictors were blood in stool, family history of IBD, and gastroenteritis/gastritis. Additionally, 14 early indicators for new-onset IBD were identified, with 86.2% of patients exhibiting ≥1 indicator within 180 days prior to IBD diagnosis. These findings suggest a need for heightened clinical suspicion for IBD in at-risk patients with PsA to support earlier recognition and diagnosis of IBD, and more informed treatment decisions.
Results from the cohorts in this real-world study were captured during routine clinical practice and are descriptive in nature only. Statistical significance has not been established.
The Medical Affairs + Health Impact department of AbbVie Inc. is the copyright owner of this presentation and has paid RheumNow to host this content. AbbVie is solely responsible for all written content within this presentation.
© 2026 AbbVie Inc. All rights reserved. ABBV-US-02460-MC. v1.0 Approved June 2026
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.